store at low temperature
store at -80°C
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 347.00 | |
5 mg | In stock | $ 886.00 | |
10 mg | In stock | $ 1,450.00 |
Description | Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours. |
In vitro | After 5 or 10 days of incubation, single-agent Xentuzumab(XENT)or ENZA reduced the viability of VCaP, DuCaP, and MDA PCa 2b cells in a dose-dependent manner. Combination therapy further decreased cell viability compared to monotherapy; likewise, treatment with XENT+ENZA resulted in a significant reduction in the expression of cell cycle genes, ubiquitin-conjugating enzyme E2 C (UBE2C), cyclin-dependent kinase 1 (CDK1), and cell division cycle protein 20 (CDC20) compared to single-agent treatment.[1]. |
In vivo | Monotherapy with ENZA did not inhibit tumor growth. However, the addition of Xentuzumab(XENT)rendered the tumors sensitive to ENZA again, leading to a significant reduction in tumor volume[1]. |
Synonyms | BI 836845 |
Molecular Weight | N/A |
CAS No. | 1417158-65-6 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Xentuzumab 1417158-65-6 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Tyrosine Kinase/Adaptors Akt IGF-1R BI 836845 inhibitor inhibit